The current COVID-19 pandemic has provoked the urgent requirement to search for effective
treatments since the implications are so huge globally as compared to the earlier pandemics.
Momentarily, there has been no effective medicine for SARS-CoV-2 infection, and supportive care
tends to be the most effective approach to treat COVID-19 patients. The rapidly growing awareness
of SARS-CoV-2 virology offers a large number of possible drug targets. The World Health Organisation
(WHO) is steadily updating the treatment protocol for COVID-19 based on the recent
clinical trials. In the present review, we have summarised the possible mode of action, clinical evidence,
consequences of dexamethasone as the therapeutic agent against Covid-19. Currently, many
corticosteroids are being tested in ongoing randomised trials. Dexamethasone could come as the
life-saving drug. Dexamethasone drug looks useful only in those patients who are already in a critical
state. We might allow dexamethasone as a fascinating shot, if the drug proves to be clinically
favourable for long-term health effects of Covid-19 recovered patients. It is commonly accepted to
reinforce approved drugs in the fight against newly emerging diseases such as COVID-19 as these
drugs have established pharmacokinetic profiles and protection. The current focus should be on the
development of novel proven therapeutics along with vaccines. There is a need for high quality,
more extensive, rapid and collaborative randomized controlled trials with more control groups.